Lessons from the European mpox outbreak: strengthening cohort research for future pandemic preparedness
Por:
Visentin, A, Nazeri, A, Peñalvo, JL, Gorska, A, Davis, RJ, Flett, RL, Simensen, VC, Langeland, N, Gaday, Q, Mirandola, M, Mazzotta, V, Nguyen, LBL, Mothe, B, Van Dijck, C, Meyerhans, A, Boesecke, C, Giaquinto, C, Judd, A and Tacconelli, E
Publicada:
1 ene 2026
Ahead of Print:
1 dic 2025
Resumen:
Background: Well-designed cohort studies are crucial for pandemic preparedness, informing evidence-based infection prevention and treatment strategies. Objectives: Following the 2022 mpox outbreak in Europe, this scoping review critically evaluates the design, implementation, and characteristics of cohort studies focusing on mpox. The aim is to inform recommendations for the Cohort Coordination Board and the COordination MEchanism for Cohorts and Trials (CoMeCT) to enhance cohort study research and improve preparedness. Sources: A comprehensive literature search was conducted in PubMed, Scopus, ClinicalTrials.gov, the European Union Clinical Trials Register, and the European Clinical Research Infrastructure Network (ECRIN) metadata repository up to December 2024. Content: Forty-nine cohorts were identified, encompassing 10 728 individuals with primary or breakthrough mpox and 34 010 individuals without mpox (vaccinated and unvaccinated). The majority of cohorts collected data prospectively (30, 63%) and were multicentre (25, 52%). The primary aims were the natural history of mpox (31, 65%); effectiveness of vaccination (15, 31%); and treatment (2, 4%). The most frequent target population was individuals at increased risk of sexually transmitted infection (18, 38%). Follow-up of participants varied widely among cohorts. Significant data heterogeneity, stemming from the inconsistent use of standardized data dictionaries, impeded data sharing and meta-analyses. Under-representation of vulnerable populations and limited biobanking further compounded these challenges. Implications: This review underscores critical gaps in the research response during the mpox outbreak. Based on these findings, we propose the following recommendations: (1) establishing and maintaining "ever-warm" cohorts of high-risk individuals during inter-epidemic periods to enable rapid data collection during future outbreaks; (2) promoting data interoperability through the development and adoption of standardized data collection tools and ontologies; (3) improving the quality of study reporting through strict adherence to relevant guidelines; and (4) strengthening European and global coordination through the establishment of collaborative research networks. Sustained investment in research infrastructure is essential for a more effective, equitable, and timely public health response to future outbreaks. Alessandro Visentin, Clin Microbiol Infect 2026;32:62 (c) 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Filiaciones:
Visentin, A:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Nazeri, A:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Peñalvo, JL:
Carlos III Hlth Inst, Natl Ctr Epidemiol, Madrid, Spain
Gorska, A:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Davis, RJ:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Flett, RL:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Simensen, VC:
Norwegian Inst Publ Hlth, Dept Vaccines & Immunisat, Div Infect Dis Control, Oslo, Norway
Langeland, N:
Norwegian Inst Publ Hlth, Dept Vaccines & Immunisat, Div Infect Dis Control, Oslo, Norway
Univ Bergen, Dept Clin Sci, Bergen, Norway
Haukeland Hosp, Natl Ctr Trop Infect Dis, Bergen, Norway
Gaday, Q:
Inserm, Agence Natl Rech Sida & Hepatites Virales Malad In, Paris, France
Mirandola, M:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Verona Univ Hosp, WHO Collaborating Ctr Sexual Hlth & Vulnerable Pop, Dept Med, Div Infect Dis, Verona, Italy
Univ Brighton, Sch Sport & Hlth Sci, Brighton, England
Mazzotta, V:
Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin & Res Dept, Rome, Italy
Nguyen, LBL:
Univ Paris Cite, Inserm, Paris, France
Ctr Invest Clin CIC Cochin Pasteur, Assistance Publ Hop Paris, Paris, France
:
Hosp Univ Germans Trias i Pujol, Dept Infect Dis, Badalona, Spain
Hosp Univ Germans Trias I Pujol, Fundacio Lluita Infecc, Badalona, Spain
IrsiCaixa, Badalona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Univ Vic Cent Univ Catalonia, Dept Infect Dis & Immun, Vic, Spain
Van Dijck, C:
Inst Trop Med, Dept Clin Sci, Antwerp, Belgium
Katholieke Univ KU Leuven, Dept Microbiol Immunol & Transplantat, Leuven, Belgium
Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Data Sci Inst, BE-3590 Diepenbeek, Belgium
Meyerhans, A:
Univ Pompeu Fabra, Dept Med & Life Sci, Barcelona, Spain
Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain
Boesecke, C:
Bonn Univ Hosp, Dept Med 1, Bonn, Germany
Giaquinto, C:
Univ Padua, Dept Womens & Childrens Hlth, Div Paediat Infect Dis, I-35128 Padua, Italy
Penta Fdn Ente Terzo Settore ETS, Padua, Italy
Judd, A:
Penta Fdn Ente Terzo Settore ETS, Padua, Italy
UCL, Med Res Council, Clin Trials Unit, London, England
Tacconelli, E:
Univ Verona, Dept Diagnost & Publ Hlth, Div Infect Dis, Verona, Italy
Green Submitted, Bronze
|